Radiopharm Theranostics Ltd (RADX) EBT (2023 - 2026)

Radiopharm Theranostics (RADX) has reported EBT for 4 consecutive years, with -$711294.1 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT rose 98.14% year-over-year to -$711294.1 in Q2 2026; TTM through Jun 2026 was -$121.4 million, a N/A change from a year earlier, with the FY2026 full-year figure at -$386415.1, up 98.99% from the prior year.
• EBT was -$711294.1 for Q2 2026 at Radiopharm Theranostics, up from -$38.2 million in the prior quarter.
• Over five years, EBT peaked at -$711294.1 in Q2 2026 and troughed at -$47.9 million in Q2 2024.
• A 4-year average of -$30.3 million and a median of -$36.4 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT sank 38.41% in 2024 and soared 98.14% in 2026, its largest moves.
• Over 4 years, EBT stood at -$34.6 million in 2023, then sank by 38.41% to -$47.9 million in 2024, then grew by 20.09% to -$38.2 million in 2025, then soared by 98.14% to -$711294.1 in 2026.
• The last three EBT figures came in at -$711294.1 (Q2 2026), -$38.2 million (Q2 2025), and -$47.9 million (Q2 2024), per Business Quant data.